MET and renal cell adenocarcinoma: Concomitantly, the genomic characterization of PRCC led to the identification of molecular alterations in the MET gene [20], suggesting the opportunity to investigate the effects of the MET inhibitors (including crizotinib) also in this RCC subtype.